Special Issue

Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile

Message from the Guest Editor

For the past forty years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin and oxaliplatin have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused in optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile.

Guest Editor

Prof. Dr. Maria Contel

Department of Chemistry, Brooklyn College and The Graduate Center, The City University of New York, Brooklyn, NY 11210, USA

Deadline for manuscript submissions

closed (31 October 2018)

Inorganics

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1

mdpi.com/si/13586

Inorganics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
inorganics@mdpi.com

mdpi.com/journal/inorganics

Inorganics

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1

mdpi.com/journal/inorganics

About the Journal

Message from the Editor-in-Chief

Inorganic chemistry remains a lynchpin of modern chemistry, not only embracing the function and reactivity of combinations of most elements of the periodic table, but also providing a footing for studies of materials, catalysts, drugs, fuels and industrial chemicals. Arguably, the role and reach of inorganics in society have never been as great as today. Adventurous research at the heart and at the extremes of inorganic chemistry is vital to further advances and Inorganics offers authors the opportunity to publish exciting new research in an open access format.

Editor-in-Chief

Prof. Dr. Duncan H. Gregory
School of Chemistry, University of Glasgow, University Avenue, Glasgow G12 8QQ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Inorganic and Nuclear) / CiteScore - Q2 (Inorganic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).